Genprex, Inc.

Genprex, Inc. announced that research from its collaboration with Meharry Medical College will be presented at the Gerontological Society of America 2026 Annual Scientific Meeting. The research focuses on the TUSC2 gene, used in Genprex's oncology candidate REQORSA, and its role in cellular resilience and aging processes. This work expands the understanding of TUSC2 and REQORSA biology, potentially informing future therapeutic applications beyond oncology, complementing Genprex's existing development in lung cancer and diabetes.

Genprex, Inc. announced it has formally regained compliance with Nasdaq's $1.00 Minimum Bid Price requirement, as notified by the Nasdaq Hearings Panel on August 4, 2026. This follows a previous exception granted on July 29, 2026, allowing the company to continue its listing. The Panel will maintain jurisdiction until December 7, 2026, during which Genprex must maintain a closing bid price at or above $1.00 for each trading day. The company also faces a seven-day window to address any other listing rule deficiencies that may arise before December 7, 2026, or risk delisting.

Genprex, Inc. announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials. This partnership builds on promising preclinical and clinical data indicating that TROP2 and PTEN H-scores can predict patient response and progression-free survival. Leveraging Roche Diagnostics' expertise and FDA Breakthrough Device Designation for a TROP2 diagnostic, Genprex aims to refine patient identification and integrate these biomarkers into its NSCLC clinical program by the end of 2026, ultimately delivering more effective, personalized treatment options.

Genprex, Inc. announced that the Nasdaq Hearings Panel has granted its request to continue listing on The Nasdaq Capital Market. The company received an exception to the $1.00 Minimum Bid Price requirement, subject to strict conditions. Genprex must demonstrate compliance by July 29, 2026, and maintain a closing bid price at or above $1.00 until December 7, 2026, with the Panel retaining jurisdiction. The company acknowledges there is no assurance it will satisfy these terms or maintain compliance.

Genprex, Inc. announced a one-for-twenty-two (1:22) reverse stock split of its common stock, effective July 16, 2026. This action will convert every 22 shares into one, with fractional shares rounded up, resulting in an estimated 504,936 shares outstanding post-split from 11,108,577 shares. The company also provided an investor presentation with business updates on its oncology and diabetes gene therapy programs, including ongoing enrollment in Phase 2a of the Acclaim-1 clinical trial.

Genprex announced it received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering Reqorsa Gene Therapy in combination with PD-1 or PD-L1 antibodies for non-small cell and small cell lung cancer. This expands its intellectual property portfolio, which already includes patents in the U.S., Japan, Europe, and other countries. The patent strengthens protection for therapeutic combinations currently being evaluated in the Acclaim-3 clinical trial. Lung cancer is a leading cause of death in Canada, with 32,900 diagnoses and 19,300 deaths estimated for 2026.

Genprex, Inc. stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split, allowing the Board to implement a ratio between one-for-five (1:5) and one-for-fifty (1:50) by December 31, 2027. Additionally, the company's amended and restated 2018 Equity Incentive Plan was approved, increasing the number of shares authorized for issuance by 1,850,000. Stockholders also elected two Class III directors, ratified the appointment of the independent registered public accounting firm, and approved the advisory vote on executive compensation.

Genprex, Inc. received a letter from Nasdaq on June 10, 2026, indicating its common stock is subject to delisting due to non-compliance with the $1.00 minimum bid price requirement over the past 30 consecutive business days. The company is ineligible for a compliance period because it previously effected a reverse stock split on October 21, 2025. Genprex intends to request a hearing before a Nasdaq Hearings Panel, which will automatically stay the delisting action, and plans to take definitive steps, including potentially another reverse stock split, to regain compliance.

Genprex announced the publication of an abstract at the 2026 ASCO Annual Meeting, detailing positive clinical data for its lead drug candidate, Reqorsa® Gene Therapy. The studies identified predictive biomarkers, Trop-2 and PTEN, that correlate with prolonged Progression Free Survival in Non-Small Cell Lung Cancer patients receiving Reqorsa. This clinical validation supports earlier preclinical findings and suggests potential for targeted patient selection and precision medicine.

Genprex, Inc. announced positive preclinical data for its diabetes gene therapy drug candidate, GPX-002 (Pdx1/MafA gene therapy), presented at the 2026 ASGCT Annual Meeting. The data demonstrated that the therapy successfully reversed hyperglycemia in Type 2 diabetic mouse models. Key findings included improved beta-cell function and maturation, with an increase in mature insulin granules, suggesting a fundamental approach to treating T2D. The company believes this preclinical data is a pivotal step towards a potentially transformative treatment offering long-term glycemic control.